Literature DB >> 25486467

Upgrading gemcitabine with recycled kinase inhibitors.

Fernando F Blanco1, Michael J Pishvaian, Jonathan R Brody.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25486467      PMCID： PMC4613457          DOI： 10.4161/15384101.2014.954211

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint.

Authors:  Xingxu Huang; Thanh Tran; Lingna Zhang; Rashieda Hatcher; Pumin Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-13       Impact factor: 11.205

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.

Authors:  Philip C De Witt Hamer; Shahryar E Mir; David Noske; Cornelis J F Van Noorden; Tom Würdinger
Journal:  Clin Cancer Res       Date:  2011-05-11       Impact factor: 12.531

4.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Authors:  H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

5.  Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.

Authors:  Laura Carrassa; Rosaria Chilà; Monica Lupi; Francesca Ricci; Cinzia Celenza; Marco Mazzoletti; Massimo Broggini; Giovanna Damia
Journal:  Cell Cycle       Date:  2012-07-01       Impact factor: 4.534

6.  Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

Authors:  V Heinemann; L Schulz; R D Issels; W Plunkett
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929

Review 7.  Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

Authors:  W Plunkett; P Huang; Y Z Xu; V Heinemann; R Grunewald; V Gandhi
Journal:  Semin Oncol       Date:  1995-08       Impact factor: 4.929
  7 in total
  1 in total

1.  microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression.

Authors:  Zhe Liu; Ruixia Du; Jin Long; Kejian Guo; Chunlin Ge; Shulong Bi; Yuanhong Xu
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.